

# A study to evaluate the safety, tolerability and processing by the body of RO7440688 in healthy volunteers

<b>Submission date</b> 05/02/2021	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 10/03/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 08/04/2024	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Current plain English summary as of 05/11/2021:

### Background and study aims

The aim of this study is to test a new drug RO744068 compared with placebo at different doses, to find out if it is safe and to understand the way people process the drug. A placebo looks like a drug but has no active ingredient.

### Who can participate?

Healthy male and female volunteers aged 18 to 65 years, inclusive

### What does the study involve?

Participants are randomly assigned to receive either RO744068 or placebo as a single dose or multiple doses to determine the safety and the way people process the drug. The total maximum study duration for participants is about 50 days.

### What are the possible benefits and risks of participating?

Participants are not expected to receive any direct benefits from the study, but the information that is learned may help other people in the future. RO744068 has not yet been tested in humans. This is the first trial of RO744068 in humans. For this reason, the side effects of this drug are not known at this time.

### Where is the study run from?

Christchurch Clinical Studies Trust (New Zealand)

### When is the study starting and how long is it expected to run for?

March 2021 to March 2022

### Who is funding the study?

Genentech, Inc. (USA)

Who is the main contact?  
global-roche-genentech-trials@gene.com

Previous plain English summary:

Background and study aims

The aim of this study is to test a new drug RO744068 compared with placebo at different doses, to find out if it is safe and to understand the way people process the drug. A placebo looks like a drug but has no active ingredient.

Who can participate?

Healthy male and female volunteers aged 18 to 65 years, inclusive

What does the study involve?

Participants are randomly assigned to receive either RO744068 or placebo as a single dose or multiple doses to determine the safety of the drug. The total maximum study duration for participants is about 50 days.

What are the possible benefits and risks of participating?

Participants are not expected to receive any direct benefits from the study, but the information that is learned may help other people in the future. RO744068 has not yet been tested in humans. This is the first trial of RO744068 in humans. For this reason, the side effects of this drug are not known at this time.

Where is the study run from?

Christchurch Clinical Studies Trust (New Zealand)

When is the study starting and how long is it expected to run for?

March 2021 to December 2021

Who is funding the study?

Genentech, Inc. (USA)

Who is the main contact?

global-roche-genentech-trials@gene.com

## Contact information

**Type(s)**

Scientific

**Contact name**

Dr Clinical Trials

**Contact details**

1 DNA Way

South San Francisco

United States of America

94080

+1 888-662-6728

global-roche-genentech-trials@gene.com

# Additional identifiers

## EudraCT/CTIS number

Nil known

## IRAS number

## ClinicalTrials.gov number

Nil known

## Secondary identifying numbers

GC42880

# Study information

## Scientific Title

A phase I, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of RO7440688, the effect of food on the pharmacokinetics of RO7440688, and the effects of RO7440688 on midazolam pharmacokinetics in healthy volunteers

## Study objectives

Current study hypothesis as of 05/11/2021:

To assess safety, tolerability, and pharmacokinetics of RO7440688 when administered to healthy volunteers.

Previous study hypothesis:

To assess safety, tolerability, and pharmacokinetics of RO7440688 when administered to healthy volunteers in single or multiple doses

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Single-centre Phase I trial including a randomized single ascending dose, food effect, and multiple ascending dose study, and a non-randomized drug-drug interaction study

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

## Treatment

### Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

### Health condition(s) or problem(s) studied

Cardiovascular disease

### Interventions

Current intervention as of 05/11/2021:

Participants will be randomized to the treatment arms via a blinded Randomization List. In the single-ascending dose (SAD) study, each cohort will evaluate oral administration of RO7440688. The initial dose of RO7440688 will be 150 mg and subsequent doses will be determined based on review of safety and PK data. In SAD and Food Effect stages, all participants will reside at the clinical research unit for 72 hours after dosing and return for a scheduled non-residential follow-up visit. MAD participants will reside at the clinical research unit through the completion of the 7 day dosing period through 72 hours after last dose and complete non-residential follow-up visits through Day 35. The drug-drug interaction cohort is not randomized. Participants will be administered midazolam and multiple doses of RO7440688 (these dose levels will be determined by MAD) and will remain in the clinical research unit through completion of the dosing period up through 24 hours after the last dose and complete residential follow-up visits through Day 38.

Previous intervention:

Participants will be randomized to the treatment arms via a blinded Randomization List. In the single-ascending dose (SAD) study, each cohort will evaluate oral administration of RO7440688. The initial dose of RO7440688 will be 150 mg and subsequent doses will be determined based on review of safety and PK data. In SAD and Food Effect stages, all participants will reside at the clinical research unit for 72 hours after dosing and return for a scheduled non-residential follow-up visit. MAD participants will reside at the clinical research unit through the completion of the 7 day dosing period through 72 hours after last dose and complete non-residential follow-up visits through Day 35.

### Intervention Type

Drug

### Phase

Phase I

### Drug/device/biological/vaccine name(s)

RO7440688

### Primary outcome measure

1. Incidence of adverse events (DAIDS toxicity grading scale) throughout the study
2. Vital signs (respiratory rate, pulse rate, and systolic and diastolic blood pressure, and temperature) measured at baseline and daily post-dose (Day 1-15 in the SAD and Food Effect cohorts, and Day 1- 35 in the MAD cohorts)
3. Clinical laboratory test results, including chemistry panel, hematology panel, lipid panel, coagulation panel, methemoglobin level and urinalysis measured at baseline and post dose (Day 1-15 in SAD and Food Effect cohorts, and Day 1-35 in the MAD cohorts)

4. ECG abnormalities as measured by 12-lead ECG throughout the course of the study (Day 1-15 in the SAD and Food Effect cohorts, and Day 1- 35 in the MAD cohorts)

### Secondary outcome measures

Current secondary outcome measures as of 05/11/2021:

1. Pharmacokinetics (PK) of RO7440688 following a single and multiple doses, and the effect of food on the PK of RO7440688 following a single dose, on the basis of plasma concentrations of RO7440688 measured at specified timepoints. The following PK parameters will be calculated if data allow:

1.1. SAD stage: AUC<sub>0-24</sub>, AUC from time 0 to last quantifiable concentration (AUC<sub>0-last</sub>), AUC from time 0 to infinity (AUC<sub>0-inf</sub>), percentage of AUC extrapolated (AUC%extrap), C<sub>max</sub>, t<sub>max</sub>, apparent clearance (CL/F), apparent volume of distribution during elimination phase (V<sub>z</sub>/F), elimination rate constant ( $\lambda$ Z), and apparent half-life (t<sub>1/2</sub>)

1.2. MAD stage: AUC<sub>0-tau</sub>, C<sub>max</sub>, t<sub>max</sub>, C<sub>trough</sub>, average concentration at steady state (C<sub>ave,ss</sub>), peak/trough fluctuation at steady state, accumulation ratios (ARs) for C<sub>max</sub> and AUC<sub>0-tau</sub> on the last versus first day of dosing, CL/F, V<sub>z</sub>/F, apparent steady-state volume of distribution (V<sub>ss</sub>/F),  $\lambda$ Z, and t<sub>1/2</sub>

1.3. Food effect stage: AUC<sub>0-24</sub>, AUC<sub>0-last</sub>, AUC<sub>0-inf</sub>, AUC%extrap, C<sub>max</sub>, t<sub>max</sub>, CL/F, V<sub>z</sub>/F,  $\lambda$ Z, t<sub>1/2</sub>, relative bioavailability of RO7440688 following a high-fat breakfast versus fasted based on AUC and C<sub>max</sub>, and relative bioavailability of RO7440688 following a low-fat breakfast versus fasted based on AUC and C<sub>max</sub> (if appropriate)

1.4 Drug-Drug Interaction stage: plasma pharmacokinetics of midazolam and its metabolite 1-hydroxy midazolam including, but not limited to AUC<sub>0-t</sub>, AUC<sub>0-inf</sub>, C<sub>max</sub>, t<sub>max</sub>, CL/F, t<sub>1/2</sub>

For SAD/food effect cohorts, PK will be collected on Day 1 (predose, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 12h post-dose), Day 2 (24h post-dose), Day 3 (48h post-dose), Day 4 (72 post-dose), and anytime during clinic visit on Day 15.

For MAD cohorts, PK will be collected on Day 1 (predose, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 12h post-dose), Day 2 (pre-dose), Day 3 (pre-dose), Day 5 (pre-dose), Day 7 (predose, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 12h post-dose), Day 8 (24h after final dose), Day 9 (48h after final dose), Day 10 (72h after final dose), and anytime during clinic visit on Day 14.

For DDI cohorts, PK will be collected on Day 1 (predose, 30 m, 1, 2, 3, 4, 6, 8, 12, 16, 20 hpost-dose), Day 2 (24 h post-Day 1 dose), Day 7-9 (predose), Day 10 (same as Day 1), Day 11 (24 h post-final dose)

Previous secondary outcome measures:

1. Pharmacokinetics (PK) of RO7440688 following a single and multiple doses, and the effect of food on the PK of RO7440688 following a single dose, on the basis of plasma concentrations of RO7440688 measured at specified timepoints. The following PK parameters will be calculated if data allow:

1.1. SAD stage: AUC<sub>0-24</sub>, AUC from time 0 to last quantifiable concentration (AUC<sub>0-last</sub>), AUC from time 0 to infinity (AUC<sub>0-inf</sub>), percentage of AUC extrapolated (AUC%extrap), C<sub>max</sub>, t<sub>max</sub>, apparent clearance (CL/F), apparent volume of distribution during elimination phase (V<sub>z</sub>/F), elimination rate constant ( $\lambda$ Z), and apparent half-life (t<sub>1/2</sub>)

1.2. MAD stage: AUC<sub>0-tau</sub>, C<sub>max</sub>, t<sub>max</sub>, C<sub>trough</sub>, average concentration at steady state (C<sub>ave,ss</sub>), peak/trough fluctuation at steady state, accumulation ratios (ARs) for C<sub>max</sub> and AUC<sub>0-tau</sub> on the last versus first day of dosing, CL/F, V<sub>z</sub>/F, apparent steady-state volume of distribution (V<sub>ss</sub>/F),  $\lambda$ Z, and t<sub>1/2</sub>

1.3. Food effect stage: AUC<sub>0-24</sub>, AUC<sub>0-last</sub>, AUC<sub>0-inf</sub>, AUC%extrap, C<sub>max</sub>, t<sub>max</sub>, CL/F, V<sub>z</sub>/F,  $\lambda$ Z, t<sub>1/2</sub>, relative bioavailability of RO7440688 following a high-fat breakfast versus fasted based on

AUC and Cmax, and relative bioavailability of RO7440688 following a low-fat breakfast versus fasted based on AUC and Cmax (if appropriate)

For SAD/food effect cohorts, PK will be collected on Day 1 (predose, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 12h post-dose), Day 2 (24h post-dose), Day 3 (48h post-dose), Day 4 (72 post-dose), and anytime during clinic visit on Day 15.

For MAD cohorts, PK will be collected on Day 1 (predose, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 12h post-dose), Day 2 (pre-dose), Day 3 (pre-dose), Day 5 (pre-dose), Day 7 (predose, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 12h post-dose), Day 8 (24h after final dose), Day 9 (48h after final dose), Day 10 (72h after final dose), and anytime during clinic visit on Day 14.

**Overall study start date**

04/02/2021

**Completion date**

21/03/2022

## **Eligibility**

**Key inclusion criteria**

1. Age  $\geq 18$  years and  $\leq 65$  years
2. Ability to comply with the study protocol, in the investigator's judgment
3. Use of contraceptive measures

**Participant type(s)**

Healthy volunteer

**Age group**

Mixed

**Lower age limit**

18 Years

**Upper age limit**

65 Years

**Sex**

Both

**Target number of participants**

116

**Total final enrolment**

67

**Key exclusion criteria**

Current participant exclusion criteria as of 05/11/2021:

1. Pregnant or breastfeeding, or intending to become pregnant during the study or within 14 days of last study drug dose for subjects in the SAD and food effect stages and 28 days for

subjects in the MAD and DDI stages

2. No comorbid conditions that may interfere with the evaluation of an investigational medical product
3. No history or evidence of substance abuse that would pose a risk to participants safety, interfere with the conduct of the study, or have an impact on the study results
4. History of severe allergic or anaphylactic reactions to human, humanized, or Current treatment with medications that are well known to prolong the QT

Previous participant exclusion criteria:

1. Pregnant or breastfeeding, or intending to become pregnant during the study or within 14 days of last study drug dose for subjects in the SAD and food effect stages and 28 days for subjects in the MAD stage
2. No comorbid conditions that may interfere with the evaluation of an investigational medical product
3. No history or evidence of substance abuse that would pose a risk to participants safety, interfere with the conduct of the study, or have an impact on the study results
4. History of severe allergic or anaphylactic reactions to human, humanized, or Current treatment with medications that are well known to prolong the QT

**Date of first enrolment**

20/04/2021

**Date of final enrolment**

11/12/2021

## **Locations**

**Countries of recruitment**

New Zealand

**Study participating centre**

**Christchurch Clinical Studies Trust**

Level 4 - 264 Antigua St.

Christchurch

New Zealand

8011

## **Sponsor information**

**Organisation**

Genentech, Inc

**Sponsor details**

1 DNA Way

South San Francisco

United States of America

94080  
+1 888 662 6728  
global.clinical\_trial\_registry@roche.com

**Sponsor type**  
Industry

**Website**  
[http://www.roche.com/about\\_roche/roche\\_worldwide.htm](http://www.roche.com/about_roche/roche_worldwide.htm)

## Funder(s)

**Funder type**  
Industry

**Funder Name**  
Genentech

## Results and Publications

**Publication and dissemination plan**  
Planned publication in a high-impact peer-reviewed journal.

**Intention to publish date**  
31/05/2023

**Individual participant data (IPD) sharing plan**  
The datasets generated during and/or analysed during the current study are not expected to be made available due to confidentiality.

**IPD sharing plan summary**  
Not expected to be made available

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		23/07/2023	08/04/2024	Yes	No